U.S. Army Medical Research and Materiel Command, DoD.
In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent No. 6,066,323 entitled “Use of Antibodies to Sialidase as Anti-infectious Agents and Anti-Inflammatory Agents” issued May 23, 2000. This patent application has been assigned to the United States Government as represented by the Secretary of the Army.
Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702-5012Start Further Info
FOR FURTHER INFORMATION CONTACT:
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664. Both telefax (301) 619-5034.End Further Info End Preamble Start Supplemental Information
Sialic acids have the ability to prevent hyposialylation of cells as competitive inhibitors of endogenous sialidse. It is now also possible to develop antibodies to mammalian sialidase that significantly reduce influx of neutrophils into inflammatory sites.Start Signature
Gregory D. Showalter,
Army Federal Register Liaison Officer.
[FR Doc. 01-7262 Filed 3-22-01; 8:45 am]
BILLING CODE 3770-08-M